Investing.comCodex · 实盘不做把握 7/10
北京时间·🕒 发布 19:04:33时区推断·⟳ 抓取 19:09:53·⚡ 决策 07-23 19:13:15 +3m22s·96.1 天前
Beam Therapeutics将于9月披露BEAM-302临床更新数据
当前只是预告9月5日至9日ERS会议期间披露BEAM-302更新数据，并未发布新的疗效或安全性结果。
📄 原文Investing.com↗ 原文
Beam Therapeutics to present BEAM-302 data at September conference
Google raises annual spending estimates amid rapid AI infrastructure build-out CAMBRIDGE, Mass. - Beam Therapeutics Inc…
不做 Beam Therapeutics（BEAM.US）
只是未来临床数据展示预告，尚无新增疗效、安全性或商业化数据，当前不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-23 · 扩散 medium · price-in 风险 medium ↗
消息传播链
- 媒体转述Beam将于2026年9月ERS大会和9月8日webcast披露BEAM-302更新数据。
关键理由
- 当前只是预告9月5日至9日ERS会议期间披露BEAM-302更新数据，并未发布新的疗效或安全性结果。
- 文中提到美国超过10万人携带两份Z等位基因且约10%已诊断，但这只是适应症背景，不是本次新增商业化数据。
主要风险
- 真正股价催化在9月8日投资者webcast及会议数据公布时点，当前提前交易容易变成日历事件噪音。
原文全文
展开原文 · 1,854 字
Google raises annual spending estimates amid rapid AI infrastructure build-out
CAMBRIDGE, Mass. - Beam Therapeutics Inc. (NASDAQ:BEAM) announced Wednesday that it will present updated clinical data from its Phase 1/2 trial of BEAM-302 for alpha-1 antitrypsin deficiency at the European Respiratory Society Congress 2026 in Barcelona, Spain, taking place September 5-9, 2026.
The company will host an investor webcast on Tuesday, September 8, 2026, at 7:00 a.m. ET to review the data. The presentation is scheduled for 9:30-10:45 a.m. CEST on the same day and will be delivered by John Hurst, M.D., Ph.D., from University College London.
BEAM-302 is a liver-targeting therapy designed to correct the PiZ mutation in patients with alpha-1 antitrypsin deficiency, an inherited genetic disorder that can cause early onset emphysema and liver disease. The treatment uses base editing technology to make an A-to-G correction of the mutation.
According to the company’s statement, more than 100,000 individuals in the U.S. have two copies of the Z allele, though only about 10% are thought to have been diagnosed. The most severe form of the condition occurs when patients have a point mutation in both copies of the SERPINA1 gene.
The company stated that correction of the PiZ mutation has been durable in patients treated in its clinical trial. Beam noted that because BEAM-302 corrects the native AAT gene in its normal genetic location, AAT levels have been observed to increase physiologically in response to infection and inflammation in treated patients.
Beam Therapeutics is a biotechnology company developing precision genetic medicines through base editing technology. The information is based on a press release statement from the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
CAMBRIDGE, Mass. - Beam Therapeutics Inc. (NASDAQ:BEAM) announced Wednesday that it will present updated clinical data from its Phase 1/2 trial of BEAM-302 for alpha-1 antitrypsin deficiency at the European Respiratory Society Congress 2026 in Barcelona, Spain, taking place September 5-9, 2026.
The company will host an investor webcast on Tuesday, September 8, 2026, at 7:00 a.m. ET to review the data. The presentation is scheduled for 9:30-10:45 a.m. CEST on the same day and will be delivered by John Hurst, M.D., Ph.D., from University College London.
BEAM-302 is a liver-targeting therapy designed to correct the PiZ mutation in patients with alpha-1 antitrypsin deficiency, an inherited genetic disorder that can cause early onset emphysema and liver disease. The treatment uses base editing technology to make an A-to-G correction of the mutation.
According to the company’s statement, more than 100,000 individuals in the U.S. have two copies of the Z allele, though only about 10% are thought to have been diagnosed. The most severe form of the condition occurs when patients have a point mutation in both copies of the SERPINA1 gene.
The company stated that correction of the PiZ mutation has been durable in patients treated in its clinical trial. Beam noted that because BEAM-302 corrects the native AAT gene in its normal genetic location, AAT levels have been observed to increase physiologically in response to infection and inflammation in treated patients.
Beam Therapeutics is a biotechnology company developing precision genetic medicines through base editing technology. The information is based on a press release statement from the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。